Your browser doesn't support javascript.
loading
CRISPR/Cas9 as a Mutagenic Factor.
Shumega, Andrey R; Pavlov, Youri I; Chirinskaite, Angelina V; Rubel, Aleksandr A; Inge-Vechtomov, Sergey G; Stepchenkova, Elena I.
Afiliação
  • Shumega AR; Department of Genetics and Biotechnology, St. Petersburg State University, 199034 St. Petersburg, Russia.
  • Pavlov YI; Eppley Institute for Research in Cancer and Allied Diseases, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
  • Chirinskaite AV; Departments of Biochemistry and Molecular Biology, Pathology and Microbiology, Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
  • Rubel AA; Center of Transgenesis and Genome Editing, St. Petersburg State University, Universitetskaja Emb., 7/9, 199034 St. Petersburg, Russia.
  • Inge-Vechtomov SG; Laboratory of Amyloid Biology, St. Petersburg State University, 199034 St. Petersburg, Russia.
  • Stepchenkova EI; Department of Genetics and Biotechnology, St. Petersburg State University, 199034 St. Petersburg, Russia.
Int J Mol Sci ; 25(2)2024 Jan 09.
Article em En | MEDLINE | ID: mdl-38255897
ABSTRACT
The discovery of the CRISPR/Cas9 microbial adaptive immune system has revolutionized the field of genetics, by greatly enhancing the capacity for genome editing. CRISPR/Cas9-based editing starts with DNA breaks (or other lesions) predominantly at target sites and, unfortunately, at off-target genome sites. DNA repair systems differing in accuracy participate in establishing desired genetic changes but also introduce unwanted mutations, that may lead to hereditary, oncological, and other diseases. New approaches to alleviate the risks associated with genome editing include attenuating the off-target activity of editing complex through the use of modified forms of Cas9 nuclease and single guide RNA (sgRNA), improving delivery methods for sgRNA/Cas9 complex, and directing DNA lesions caused by the sgRNA/Cas9 to non-mutagenic repair pathways. Here, we have described CRISPR/Cas9 as a new powerful mutagenic factor, discussed its mutagenic properties, and reviewed factors influencing the mutagenic activity of CRISPR/Cas9.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistemas CRISPR-Cas / Mutagênicos Idioma: En Revista: Int J Mol Sci Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Federação Russa

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistemas CRISPR-Cas / Mutagênicos Idioma: En Revista: Int J Mol Sci Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Federação Russa